MAVENCLAD™ (cladribine tablets) │ EMD Serono
We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck KGaA, Darmstadt, Germany representative.
This page requires you to register for an account with Merck KGaA, Darmstadt, Germany.

{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

Welcome to MAVENCLAD™

Mavenclad welcome Mavenclad welcome

Click here for additional safety information and for a link to the product monograph discussing:

  • Contraindications in patients with increased risk for opportunistic infections, latent or active infections, a history of progressive multifocal leukoencephalopathy (PML), active malignancy, moderate or severe renal impairment and patients who are pregnant or breastfeeding.
  • Relevant warnings and precautions regarding malignancy; patients who require blood transfusion; increased risk of infection; elderly patients; patients with moderate or severe hepatic impairment; patients with fructose intolerance; additive hematological adverse reactions with concomitant medications; decreases in lymphocyte count, neutrophil count, red blood cell count, hematocrit, hemoglobin or platelet count; activation of latent infections; risk of active vaccine infection; evaluating for complete blood count, active and inactive tuberculosis infection, hepatitis B and C viruses, varicella-zoster antibody status, pregnancy, lymphocyte counts; vaccination; risk of PML; use of contraception; serious risk to the fetus.
  • Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.



Demonstrated efficacy

Dosing and administration




Explore MAVENCLAD’s efficacy.

Learn more

View MAVENCLAD’s weight-based
dosing regimen.1    

Learn more

Understand MAVENCLAD’s MOA.

Learn more


Discover MAVENCLAD’s monitoring.

Learn more

Read about MAVENCLAD’s patient
experience, which is supported by 4
years of clinical trial experience and
up to 8 years of follow-up
experience with over 10,000 patient-years.2

Learn more

Learn about MAVENCLAD’s safety and tolerability profile.

Learn more

  1. MAVENCLAD™ Product Monograph. EMD Serono. November 2017.
  2. Letter on file. EMD Serono. December 2017.

You are leaving our website

You are now leaving our website. This link may lead to a resource maintained by third parties over whom we have no control. As such, we are not responsible for and make no representation to the accuracy or any other aspect of such resource or the privacy practices of such third party. Providing links to a third-party website does not constitute an endorsement by our company of such website or the information or products presented on such website.